Entrada Therapeutics, Inc.
TRDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,614 | $1,950 | $20,558 | $37,398 |
| % Growth | -17.2% | -90.5% | -45% | – |
| Cost of Goods Sold | $38,361 | $0 | $0 | $0 |
| Gross Profit | -$36,747 | $1,950 | $20,558 | $37,398 |
| % Margin | -2,276.8% | 100% | 100% | 100% |
| R&D Expenses | $38,361 | $37,877 | $32,074 | $33,406 |
| G&A Expenses | $10,304 | $10,922 | $10,274 | $9,859 |
| SG&A Expenses | $10,304 | $10,922 | $10,274 | $9,859 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$38,361 | $0 | $0 | $0 |
| Operating Expenses | $10,304 | $48,799 | $42,348 | $43,265 |
| Operating Income | -$47,051 | -$46,849 | -$21,790 | -$5,867 |
| % Margin | -2,915.2% | -2,402.5% | -106% | -15.7% |
| Other Income/Exp. Net | $3,571 | $3,924 | $4,441 | $5,128 |
| Pre-Tax Income | -$43,480 | -$42,925 | -$17,349 | -$739 |
| Tax Expense | $654 | $178 | $0 | -$1,870 |
| Net Income | -$44,134 | -$43,103 | -$17,349 | $1,131 |
| % Margin | -2,734.4% | -2,210.4% | -84.4% | 3% |
| EPS | -1.06 | -1.04 | -0.42 | 0.028 |
| % Growth | -1.9% | -147.6% | -1,616.2% | – |
| EPS Diluted | -1.06 | -1.04 | -0.42 | 0.026 |
| Weighted Avg Shares Out | 41,463 | 41,339 | 41,074 | 40,843 |
| Weighted Avg Shares Out Dil | 41,463 | 41,339 | 41,074 | 43,050 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3,924 | $4,441 | $5,128 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,230 | $1,034 | $946 | $992 |
| EBITDA | -$42,250 | -$45,815 | -$20,844 | -$4,875 |
| % Margin | -2,617.7% | -2,349.5% | -101.4% | -13% |